Award type :
Product Development Award
Product Development Award
Product type :
Therapeutics
Therapeutics
Award year :
2021
2021
Project start date :
10 / 27 / 2021
10 / 27 / 2021
Project end date :
04 / 15 / 2022
04 / 15 / 2022
Project duration (months) :
12
12
Development stage :
Preclinical
Preclinical
Target disease :
Dengue
Dengue
Region served :
World
World
Recipient organization / Country of funding recipient organization :
St George's University of London (SGUL) / UK
St George's University of London (SGUL) / UK
Collaborator(s) / Country :
Jeonbuk National University / Republic of Korea
Jeonbuk National University / Republic of Korea
Funding amount(KRW) :
223,738,000
223,738,000
In order to eliminate the risk of antibody dependent enhancement (ADE), St. George’s University of London is developing a polymeric anti-dengue IgG construct with LALA mutation, in collaboration with Jeonbuk National University and Genecell Biotech. The project aims to develop an innovative polymeric antibody construct that is superior to conventional neutralizing monoclonal IgG antibodies. The new plant-based protein expression system promises broader applications for reducing manufacturing price, thereby making antibody therapies accessible to patients in LMICs.